Annotation Detail

Information
Associated Genes
ALK
Associated Variants
ALK EML4-ALK
Associated Disease
lung non-small cell carcinoma
Source Database
CIViC Evidence
Description
EML4-ALK variant 1 containing H-3122 NSCLC cells were treated with second generation ALK inhibitor PF-06463922. PF-06463922 was 125x more potent at reducing cell viability than crizotinib. Control neuroblastoma cell lines with wild-type ALK did not show inhibition below 3800 nM with either drug. At values of 10 and 100 nM, PF-06463922 showed increased ability to inhibit ALK 1278 tyrosine phosphorylation in H3122 cells.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1332
Gene URL
https://civic.genome.wustl.edu/links/genes/1
Variant URL
https://civic.genome.wustl.edu/links/variants/5
Rating
2
Evidence Type
Predictive
Disease
Lung Non-small Cell Carcinoma
Evidence Direction
Supports
Drug
Lorlatinib
Evidence Level
D
Clinical Significance
Sensitivity/Response
Pubmed
26554404
Drugs
Drug NameSensitivitySupported
LorlatinibSensitivitytrue